These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 18928537)

  • 1. Positron Emission Tomography (PET) radiotracers in oncology--utility of 18F-Fluoro-deoxy-glucose (FDG)-PET in the management of patients with non-small-cell lung cancer (NSCLC).
    Miele E; Spinelli GP; Tomao F; Zullo A; De Marinis F; Pasciuti G; Rossi L; Zoratto F; Tomao S
    J Exp Clin Cancer Res; 2008 Oct; 27(1):52. PubMed ID: 18928537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Value of FDG PET in the management of NSCLC.
    Ukena D; Hellwig D
    Lung Cancer; 2004 Aug; 45 Suppl 2():S75-8. PubMed ID: 15552785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Positron emission tomography imaging in nonsmall-cell lung cancer.
    Erasmus JJ; Macapinlac HA; Swisher SG
    Cancer; 2007 Nov; 110(10):2155-68. PubMed ID: 17896784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of Molecular Imaging with 2-Deoxy-2-[Fluorine-18] Fluoro-DGlucose Positron Emission Tomography (18F-FDG PET) for Small Cell Lung Cancer (SCLC): A Radiation Oncology Perspective.
    Sager O; Dincoglan F; Demiral S; Uysal B; Gamsiz H; Elcim Y; Gundem E; Dirican B; Beyzadeoglu M
    Curr Radiopharm; 2019; 12(1):4-10. PubMed ID: 30465520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value of FDG-PET in the management of non-small cell lung cancer.
    Stroobants S; Verschakelen J; Vansteenkiste J
    Eur J Radiol; 2003 Jan; 45(1):49-59. PubMed ID: 12499064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
    Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognosis and reevaluation of lung cancer by positron emission tomography imaging.
    Erasmus JJ; Rohren E; Swisher SG
    Proc Am Thorac Soc; 2009 Apr; 6(2):171-9. PubMed ID: 19349485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple distant muscular metastases from non-small cell lung carcinoma evidenced by 18F-FDG PET/CT.
    Caobelli F; Pizzocaro C; Guerra UP
    Rev Esp Med Nucl Imagen Mol; 2013; 32(5):338-9. PubMed ID: 23809515
    [No Abstract]   [Full Text] [Related]  

  • 9. 11C-Acetate can be used in place of 18F-fluorodeoxyglucose for positron emission tomography imaging of non-small cell lung cancer with higher sensitivity for well-differentiated adenocarcinoma.
    Nomori H; Shibata H; Uno K; Iyama K; Honda Y; Nakashima R; Sakaguchi K; Goya T; Takanami I; Koizumi K; Suzuki T; Kaji M; Horio H
    J Thorac Oncol; 2008 Dec; 3(12):1427-32. PubMed ID: 19057268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of FDG-PET in the diagnosis and management of lung cancer.
    Oyen WJ; Bussink J; Verhagen AF; Corstens FH; Bootsma GP
    Expert Rev Anticancer Ther; 2004 Aug; 4(4):561-7. PubMed ID: 15270660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of fluorodeoxyglucose positron emission tomography in non-small cell lung cancer: a review.
    Pillot G; Siegel BA; Govindan R
    J Thorac Oncol; 2006 Feb; 1(2):152-9. PubMed ID: 17409845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Positron emission tomography/computed tomography in lung cancer staging, prognosis, and assessment of therapeutic response.
    Truong MT; Viswanathan C; Erasmus JJ
    J Thorac Imaging; 2011 May; 26(2):132-46. PubMed ID: 21508735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The lung cancers: staging and response, CT,
    Owens C; Hindocha S; Lee R; Millard T; Sharma B
    Br J Radiol; 2023 Aug; 96(1148):20220339. PubMed ID: 37097296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of whole-body ¹⁸F-fluorodeoxyglucose positron emission tomography on therapeutic management of non-small cell lung cancer.
    Heo EY; Yang SC; Yoo CG; Han SK; Shim YS; Kim YW
    Respirology; 2010 Nov; 15(8):1174-8. PubMed ID: 20573060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imaging in lung cancer: positron emission tomography scan.
    Vansteenkiste JF
    Eur Respir J Suppl; 2002 Feb; 35():49s-60s. PubMed ID: 12064681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDG-PET for lymph node staging in NSCLC: a major step forward, but beware of the pitfalls.
    Vansteenkiste JF
    Lung Cancer; 2005 Feb; 47(2):151-3. PubMed ID: 15639713
    [No Abstract]   [Full Text] [Related]  

  • 17. Role of 18F-FDG PET in assessment of response in non-small cell lung cancer.
    Hicks RJ
    J Nucl Med; 2009 May; 50 Suppl 1():31S-42S. PubMed ID: 19380411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of FDG-PET in the management of non-small cell lung carcinoma.
    Ho Shon IA; Maisey MN
    Ann Acad Med Singap; 2004 Mar; 33(2):166-74. PubMed ID: 15098629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrated FDG-PET/CT does not make invasive staging of the intrathoracic lymph nodes in non-small cell lung cancer redundant: a prospective study.
    Tournoy KG; Maddens S; Gosselin R; Van Maele G; van Meerbeeck JP; Kelles A
    Thorax; 2007 Aug; 62(8):696-701. PubMed ID: 17687098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response to radiation.
    Rosenzweig KE; Fox JL; Giraud P
    Semin Radiat Oncol; 2004 Oct; 14(4):322-5. PubMed ID: 15558507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.